

The background of the cover is a blurred medical scene, possibly a patient's arm being examined. Overlaid on this is a semi-transparent green geometric pattern consisting of lines and shapes. Various medical icons are scattered throughout: a syringe in the upper right, a pill in the middle left, a virus/cell in the center, a stethoscope in the bottom left, and a group of three people in the center. A large green cross is positioned in the center, partially overlapping the word 'MEDICAL' which is faintly visible on the background image.

Louisiana Department of Health

**Comparison of
Health Plan Encounter Data to
Cash Disbursements for
Louisiana Healthcare Connections
July 1, 2023 – June 30, 2025**

September 11, 2025



Table of Contents

■ Study Purpose.....	3
■ Summary	4
• Entire Plan	4
• Table A – LHCC Entire Plan Summary Table	4
• Encounter Data Analysis.....	5
• Summary Charts	6
• Data Issues and Recommendations	7
• Value-Added Services (VAS)	10
■ Monthly Tables	13
• Entire Plan	13
• Envolve Vision	14
• Envolve Dental.....	15
• Veyo (NEMT).....	16
• MediTrans (NEMT)	17
• CVS Health (Pharmacy).....	18
• Prime Therapeutics (Pharmacy)	19
• Non-Vendor	20
■ Appendix A: VAS Monthly Tables.....	21
• Entire Plan VAS.....	21
• Envolve Vision VAS	22
• Envolve Dental VAS	23
• Veyo (NEMT) VAS	24
• MediTrans (NEMT) VAS	25
• Non-Vendor VAS.....	26
■ Appendix B: Definitions and Acronyms	27
■ Appendix C: Analysis	29
■ Appendix D: Data Analysis Assumptions	30

Study Purpose

Louisiana Department of Health (LDH) engaged Myers and Stauffer LC to analyze Healthy Louisiana encounter data that has been submitted by the managed care organizations (MCO) to Louisiana's fiscal agent contractor (FAC), Gainwell, and complete a comparison of the encounters to cash disbursement journals provided by each MCO. For purposes of this analysis, "encounter data" are claims that have been paid by Louisiana Healthcare Connections (LHCC) or delegated vendors (e.g., vision and pharmacy) to health care providers that have provided health care services to members enrolled with the MCO. Encounter data is submitted to LDH via the FAC for LDH's use in rate setting, federal reporting, program management and oversight, tracking, accounting, ad hoc analyses, and other activities.

LDH requested that, for this study, we estimate the percentage of each MCO delegated vendor's paid encounters that appear to be included in the FAC's database. This analysis includes these percentages for the entire plan, as well as separate vision, non-emergency medical transportation (NEMT), dental value-added service (VAS), and pharmacy delegated vendor encounters paid during the reporting period. We have also included the percentages for total non-vendor MCO paid encounters.

Our work was performed in accordance with American Institute of Certified Public Accountants (AICPA) professional standards for consulting engagements. We were not engaged to, nor did we perform, an audit, examination, or review services; accordingly, we express no opinion or conclusion related to the procedures performed or the information and documentation we reviewed. In addition, our engagement was not specifically designed for, and should not be relied on, to disclose errors, fraud, or other illegal acts that may exist.

The results of our engagement and this report are intended only for the internal use of the LDH and should not be used for any other purpose.

Summary

Entire Plan

LDH requested that, for this study, we review the plan's paid encounters to determine if the paid encounters meet the state contract completeness range of **99 percent to 100 percent** when compared to the cash disbursement journal (CDJ) files that are submitted by the MCO. The new pharmacy vendor, Prime Therapeutics, effective October 28, 2023, has a state contract completeness range of 97 percent to 100 percent. The encounters and CDJ file utilized in this study met the following criteria:

- Encounter and CDJ transactions were paid within the reporting period of **July 1, 2023 through June 30, 2025**.
- Encounters were received and accepted by the FAC and transmitted to Myers and Stauffer LC through **July 29, 2025**.

Table A – LHCC Entire Plan Summary Table

Table A — LHCC Cumulative Completion Totals and Percentages								
Description	Entire Plan	Non-Vendor	Delegated Vendor					
			Envolve Vision	Envolve Dental	Veyo (NEMT)	MediTrans (NEMT)	CVS Health (Pharmacy)	Prime Therapeutics (Pharmacy)
Encounter Total (FAC reported)	\$5,540,674,796	\$3,417,345,354	\$39,310,859	\$5,038,884	\$64,854,360	\$1,662,396	\$729,585,316	\$1,282,877,626
Total Encounter Adjustments (\$)	(\$1,091,545,852)	(\$647,747,027)	(\$3,838,132)	(\$353,332)	(\$2,950,571)	(\$259,962)	(\$410,178,438)	(\$26,218,390)
Total Encounter Adjustments (%)	-19.70%	-18.95%	-9.76%	-7.01%	-4.54%	-15.63%	-56.22%	-2.04%
Net Encounter Total	\$4,449,128,944	\$2,769,598,328	\$35,472,728	\$4,685,552	\$61,903,788	\$1,402,435	\$319,406,878	\$1,256,659,236
CDJ Total	\$4,542,682,813	\$2,853,049,380	\$36,207,394	\$4,654,530	\$62,140,187	\$2,062,782	\$295,480,628	\$1,289,087,912
Variance	(\$93,553,869)	(\$83,451,053)	(\$734,666)	\$31,022	(\$236,399)	(\$660,347)	\$23,926,251	(\$32,428,676)
Completion (%)	97.94%	97.07%	97.97%	100.66%	99.61%	67.98%	108.09%	97.48%
100% Limited Completion* (%)	97.41%	N/A	N/A	100.00%	N/A	N/A	100.00%	N/A
Minimum Completeness (%)	^	99.00%						97.00%
Non-Compliant (%)	^	-1.93%	-1.03%	0.66%	N/A	-31.02%	8.09%	N/A

* To avoid overstating the Entire Plan results in situations where an individual vendor's cumulative completion percentage exceeds 100 percent, we have decreased the Entire Plan encounter totals by the total variance in comparison to the CDJ. Please see Appendix B for more information on the limited completion percentage.

^ The Entire Plan Minimum Completeness and Non-Compliant percentages cannot be stated since the single PBM, Prime Therapeutics, has a minimum threshold of 97 percent which differs from the other delegated vendors that all have a 99 percent minimum threshold.



Encounter Data Analysis

For this study, Myers and Stauffer analyzes the encounter data that is submitted by the MCO to the FAC and loaded into the FAC Medicaid Management Information System (MMIS). Encounters submitted by the MCO that were rejected by the FAC for errors in submission or other reasons are not transmitted to Myers and Stauffer.

Furthermore, Myers and Stauffer analyzes the encounter data from the FAC MMIS and makes the following adjustments. Table B below outlines the impact of applying these encounter analysis adjustments to the encounter paid amounts, when compared to the raw data received.

1. The payment amounts associated with denied encounters are identified as zero dollars in the encounter reconciliation analysis since they bear no impact on cash disbursements.
2. We identified potential duplicate encounters using our encounter review logic. Based on a comparison to the CDJ files, we noted some of these potential duplicates appear to be partial payments, some are actual duplicate submissions, and some are replacement encounters without a matching void. At the direction of LDH, we have attempted to adjust our totals to reflect the actual payment made and have removed duplicate payment amounts from our analysis.

Table B — Myers and Stauffer LC's Adjustments to LHCC Encounters

Description	Encounter Count	Paid Amount	Paid Amount (% of Total*)
Total Encounter Amount (FAC Reported)	83,917,221	\$5,540,674,796	100.00%
Adjustment Type			
State System Denied	(6,219,702)	(\$1,083,258,801)	-19.55%
Health Plan Denied	(16,475,434)	(\$1,330,880)	-0.02%
Calculated Void	(192,823)	(\$5,474,730)	-0.09%
Duplicate	(14,614)	(\$1,481,441)	-0.02%
Total Adjustments Made	(22,902,573)	(\$1,091,545,852)	-19.70%
Net Encounter Amounts	61,014,648	\$4,449,128,944	80.30%

* Due to rounding, the sum of the displayed percentages in this report may not add up to the total.



Summary Charts

Chart 1. Entire Plan CDJ and Encounter Totals by Paid Month





Chart 2. Entire Plan Completion Percentage by Paid Month





Data Issues and Recommendations

During this analysis, Myers and Stauffer identified potential data issues that may impact the completion percentages for LHCC. Section A details issues related to non-compliant cumulative completion percentages, while Section B notes outstanding data issues that LHCC may need to work to identify and resolve.

Please reference Tables 1 through 8 for LHCC reconciliation period tables. These tables contain detailed reconciliation totals, completion percentages, and encounter analysis adjustments.

Section A: Data issues potentially impacting compliance:

1. **Engolve Vision** (Table 2): The cumulative completion percentage is below the 99 percent threshold at 97.97 percent. There are currently sixteen months where the monthly completion percentages are below the 99 percent threshold. Additionally, there is one month where the monthly completion percentage is above the 100 percent threshold.
 - The low percentages for December 2023 through July 2024 and October 2024 through May 2025 appear to be due to state system denied encounters and void CDJ transactions occurring in different months than their corresponding void encounter transactions.
 - The high percentage for September 2024 appears to be due to void encounter transactions occurring in different months than their corresponding void CDJ transactions and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.

We recommend LHCC work with Engolve Vision, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter data submissions.

2. **Engolve Dental** (Table 3): The cumulative completion percentage is above the 100 percent threshold at 100.66 percent. There is currently one month where the monthly completion percentage is below the 99 percent threshold. Additionally, there are eight months where the monthly completion percentages are above the 100 percent threshold. Engolve Dental was no longer an active vendor after December 2023.
 - The low completion percentage for October 2023 appears to be due to state system denied encounters.
 - The high percentages for November 2023 and January 2024 through July 2024 appear to be due to missing void encounters when compared to their corresponding void CDJ transactions, missing CDJ transactions when compared to their corresponding encounter transactions, and encounter transactions occurring in different months than their corresponding CDJ transactions.

We recommend LHCC work with Engolve Dental, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter data submissions.



3. **MediTrans** (Table 5): The cumulative completion percentage is below the 99 percent threshold at 67.98 percent. There are two months where the monthly completion percentages are below the 99 percent threshold.

- The low completion percentages for May 2025 and June 2025 appear to be due to missing encounters and state system denied encounters.

We recommend LHCC work with MediTrans, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter data submissions.

4. **CVS Health** (Table 6): CVS Health's cumulative completion percentage is above the 100 percent threshold at 108.09 percent. There are thirteen months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are three months where the monthly completion percentages are above the 100 percent threshold. CVS Health became an inactive vendor as of October 28, 2023.

- The high and low percentages appear to be due to mismatched paid dates and amounts between the paid months. These mismatches may be due to CDJ void transactions and encounter void transactions not matching for the same paid month.

We recommend LHCC work with CVS, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter submissions.

5. **Non-Vendor** (Table 8): The cumulative completion percentage is below the 99 percent threshold at 97.07 percent. There are twenty-one months where the monthly completion percentages are below the 99 percent threshold. Additionally, there is currently one month where the monthly completion percentage is above the 100 percent threshold.

- The low percentages for July 2023, November 2023 through January 2025, and April 2025 appear to be due to state system denied encounters and void encounter transactions occurring in different months than the corresponding void CDJ transactions.
- The low percentages for February 2025, March 2025, May 2025, and June 2025 appear to be due to missing encounter transactions, state system denied encounters, and void encounter transactions occurring in different months than the corresponding void CDJ transactions.

We recommend LHCC work with LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter submissions.



Section B: Data issues not currently impacting compliance:

6. **Veyo** (Table 4): The cumulative completion percentage is above the 99 percent threshold at 99.61 percent. There are currently eight months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are eight months where the monthly completion percentages are above the 100 percent threshold. Veyo was replaced by MediTrans effective May 1, 2025.
- The low percentages for December 2024 and February 2025 through June 2025 appear to be due to encounter transactions occurring in different months than the corresponding CDJ transactions and state system denied encounters.
 - The high percentages for March 2024, May 2024, and August 2024 through November 2024 appear to be due to missing CDJ transactions.

We recommend LHCC work with Veyo, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter submissions.

7. **Prime Therapeutics** (Table 7): The cumulative completion percentage is above the 97 percent threshold at 97.48 percent. There are three months where the monthly completion percentages are below the 97 percent threshold. Additionally, there are seven months where the monthly completion percentages are above the 100 percent threshold.
- The low percentage for November 2023 appears to be due to void CDJ transactions occurring in later months than their corresponding void encounter transactions and state system denied encounters.
 - The low percentages for November 2024 and April 2025 appear to be due to many instances where the CDJ transaction has a non-zero paid amount while the corresponding encounter transaction has a zero paid amount.
 - The high percentages for February 2024, July 2024, and August 2024 appear to be due to void encounter transactions occurring in earlier months than their corresponding void CDJ transactions.
 - The high percentages for June 2024, December 2024, and June 2025 appear to be due to missing void encounters and void encounter transactions occurring in earlier months than their corresponding void CDJ transactions.

We recommend LHCC work with Prime Therapeutics, LDH and Gainwell to identify and correct any potential issues with CDJ and/or encounter submissions.



Value-Added Services (VAS)

Value-added services are included in the MCO's vision, dental, and non-vendor CDJ and encounter totals. VAS CDJ data is identified based on the activity type field of the CDJ files received from the MCO and VAS encounter data is identified based on the first two characters of the Plan ICN field.

Below is a summary of the cumulative completion percentages for all delegated vendor and non-vendor paid VAS encounters submitted to Gainwell, for the reporting period. The VAS CDJ and encounter totals in the table below are included in the entire plan, non-vendor and delegated vendor completion percentage tables as well.

Table C — LHCC VAS Cumulative Completion Totals and Percentages						
Description	Entire Plan VAS	Non-Vendor VAS	Delegated Vendor			
			Envolve Vision VAS	Envolve Dental VAS	Veyo VAS (NEMT)	MediTrans VAS (NEMT)
Encounter Total (FAC reported)	\$20,709,302	\$2,279,076	\$11,648,723	\$5,038,884	\$1,691,137	\$51,483
Total Encounter Adjustments (\$)	(\$1,873,239)	(\$269,782)	(\$943,343)	(\$353,332)	(\$295,839)	(\$10,942)
Total Encounter Adjustments (%)	-9.04%	-11.83%	-8.09%	-7.01%	-17.49%	-21.25%
Net Encounter Total	\$18,836,063	\$2,009,294	\$10,705,379	\$4,685,552	\$1,395,298	\$40,540
CDJ Total	\$19,074,784	\$1,929,799	\$10,951,545	\$4,654,530	\$1,491,156	\$47,754
Variance	(\$238,721)	\$79,495	(\$246,166)	\$31,022	(\$95,858)	(\$7,214)
Completion (%)	98.74%	104.11%	97.75%	100.66%	93.57%	84.89%
100% Limited Completion (%)	98.16%	100.00%	N/A	100.00%	N/A	N/A
Minimum Completeness (%)	99.00%					
Non-Compliant (%)	-0.26%	4.11%	-1.25%	0.66%	-5.43%	-14.11%

* To avoid overstating the VAS Entire Plan results in situations where an individual vendor's cumulative completion percentage exceeds 100 percent, we decrease the Entire Plan encounter totals by the total variance in comparison to the CDJ. Please see Appendix B for more information on the limited completion percentage.



Potential VAS data issues:

1. **Envolve Vision VAS** (Table 2V): The cumulative completion percentage for Envolve Vision VAS is below the 99 percent threshold at 97.75 percent. The monthly completion percentages are below the 99 percent threshold for fifteen months. The monthly completion percentages are above 100 percent for two months.
 - The low percentages in April 2024 through July 2024, October 2024 through December 2024, and February 2025 through April 2025 appear to be primarily due to state system denied encounters.
 - The low percentage in December 2023 appears to be due to state system denied encounters and encounter transactions occurring in different months than their corresponding CDJ transactions.
 - The low percentage in September 2024 appear to be due to state system denied encounters and VAS encounters identified as non-VAS instead of VAS.
2. **Veyo VAS** (Table 4V): The cumulative completion percentage for Veyo VAS is below the 99 percent threshold at 93.57 percent. The monthly completion percentages are below the 99 percent threshold for sixteen months. The monthly completion percentages are above 100 percent for eight months. Veyo was replaced by MediTrans effective May 1, 2025.
 - The low percentages in July 2023, August 2023, and June 2024 through June 2025 appear to be due to state system denied encounters.
 - The high percentages in October 2023 through May 2024 appear to be due to VAS CDJ transactions identified as non-VAS instead of VAS.
3. **MediTrans VAS**(Table 5V): MediTrans VAS cumulative completion percentage is below the 99 percent threshold at 84.89 percent. There is one month where the monthly completion percentage is below the 99 percent threshold.
 - The low completion percentage for June 2025 appears to be due to missing encounters and state system denied encounters.
4. **Non-Vendor VAS** (Table 6V): The cumulative completion percentage for Non-Vendor VAS is above the 100 percent threshold at 104.11 percent. The monthly completion percentages are below the 99 percent threshold for five months. The monthly completion percentages are above 100 percent for eighteen months.
 - The high percentages appear to be due to non-VAS encounters identified as VAS instead of non-VAS and/or VAS CDJ transactions identified as non-VAS instead of VAS and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.



- The low percentages in April 2024, August 2024, and October 2024 through December 2024 appear to be due to state system denied encounters and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.



Monthly Tables

Entire Plan

Table 1 — LHCC (Entire Plan)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$210,578,476	(\$33,178,872)	-15.75%	\$177,399,604	\$179,583,152	(\$2,183,547)	98.78%
August 2023	\$702,107,060	(\$454,543,615)	-64.73%	\$247,563,445	\$226,825,495	\$20,737,950	109.14%
September 2023	\$222,900,751	(\$26,525,643)	-11.90%	\$196,375,108	\$197,820,409	(\$1,445,301)	99.26%
October 2023	\$219,223,671	(\$21,046,042)	-9.60%	\$198,177,629	\$197,879,409	\$298,221	100.15%
November 2023	\$228,222,748	(\$25,783,832)	-11.29%	\$202,438,917	\$207,125,780	(\$4,686,863)	97.73%
December 2023	\$223,062,642	(\$32,785,391)	-14.69%	\$190,277,251	\$193,087,234	(\$2,809,982)	98.54%
January 2024	\$231,783,182	(\$33,406,737)	-14.41%	\$198,376,445	\$205,150,960	(\$6,774,515)	96.69%
February 2024	\$206,397,114	(\$29,345,651)	-14.21%	\$177,051,463	\$178,367,293	(\$1,315,829)	99.26%
March 2024	\$204,722,078	(\$27,126,157)	-13.25%	\$177,595,921	\$182,841,529	(\$5,245,608)	97.13%
April 2024	\$218,490,506	(\$20,769,818)	-9.50%	\$197,720,688	\$203,972,666	(\$6,251,978)	96.93%
May 2024	\$207,427,176	(\$28,398,656)	-13.69%	\$179,028,519	\$183,347,228	(\$4,318,708)	97.64%
June 2024	\$221,462,409	(\$35,987,247)	-16.24%	\$185,475,162	\$187,641,315	(\$2,166,153)	98.84%
July 2024	\$240,602,353	(\$35,754,777)	-14.86%	\$204,847,576	\$206,076,825	(\$1,229,249)	99.40%
August 2024	\$208,854,955	(\$28,934,814)	-13.85%	\$179,920,141	\$181,755,534	(\$1,835,392)	98.99%
September 2024	\$202,629,917	(\$30,457,762)	-15.03%	\$172,172,155	\$174,559,230	(\$2,387,075)	98.63%
October 2024	\$234,423,471	(\$29,818,769)	-12.72%	\$204,604,702	\$208,722,510	(\$4,117,808)	98.02%
November 2024	\$206,160,778	(\$36,155,480)	-17.53%	\$170,005,298	\$188,433,846	(\$18,428,548)	90.22%
December 2024	\$249,618,895	(\$47,947,795)	-19.20%	\$201,671,099	\$204,605,705	(\$2,934,606)	98.56%
January 2025	\$181,742,206	(\$16,635,894)	-9.15%	\$165,106,312	\$166,224,690	(\$1,118,378)	99.32%
February 2025	\$209,272,544	(\$47,337,272)	-22.61%	\$161,935,273	\$167,040,147	(\$5,104,875)	96.94%
March 2025	\$175,978,265	(\$16,660,685)	-9.46%	\$159,317,580	\$165,652,475	(\$6,334,896)	96.17%
April 2025	\$196,939,433	(\$13,974,046)	-7.09%	\$182,965,386	\$201,775,971	(\$18,810,585)	90.67%
May 2025	\$177,336,379	(\$10,623,242)	-5.99%	\$166,713,137	\$170,551,999	(\$3,838,863)	97.74%
June 2025	\$160,737,785	(\$8,347,655)	-5.19%	\$152,390,130	\$163,641,410	(\$11,251,280)	93.12%
Cumulative Totals	\$5,540,674,796	(\$1,091,545,852)	-19.70%	\$4,449,128,944	\$4,542,682,813	(\$93,553,869)	97.94%
100% Limited Cumulative Total				\$4,425,171,672	\$4,542,682,813	(\$117,511,141)	97.41%
Minimum Completeness (%)							See Table A ^
Non-Compliant							See Table A ^



Engolve Vision

Table 2 — LHCC Engolve Vision

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$1,396,735	(\$37,854)	-2.71%	\$1,358,881	\$1,362,483	(\$3,602)	99.73%
August 2023	\$2,037,605	(\$59,917)	-2.94%	\$1,977,688	\$1,977,683	\$4	100.00%
September 2023	\$1,511,653	(\$26,377)	-1.74%	\$1,485,275	\$1,496,344	(\$11,069)	99.26%
October 2023	\$1,537,478	(\$24,723)	-1.60%	\$1,512,755	\$1,513,999	(\$1,244)	99.91%
November 2023	\$1,703,636	(\$35,185)	-2.06%	\$1,668,451	\$1,682,631	(\$14,180)	99.15%
December 2023	\$1,149,074	(\$15,712)	-1.36%	\$1,133,363	\$1,164,236	(\$30,873)	97.34%
January 2024	\$1,245,874	(\$35,712)	-2.86%	\$1,210,162	\$1,230,883	(\$20,720)	98.31%
February 2024	\$1,534,906	(\$44,453)	-2.89%	\$1,490,452	\$1,522,256	(\$31,803)	97.91%
March 2024	\$1,576,443	(\$60,512)	-3.83%	\$1,515,931	\$1,559,731	(\$43,800)	97.19%
April 2024	\$1,570,521	(\$171,482)	-10.91%	\$1,399,040	\$1,493,634	(\$94,594)	93.66%
May 2024	\$1,757,655	(\$145,397)	-8.27%	\$1,612,258	\$1,687,957	(\$75,699)	95.51%
June 2024	\$1,397,223	(\$92,606)	-6.62%	\$1,304,616	\$1,352,166	(\$47,550)	96.48%
July 2024	\$1,719,730	(\$112,747)	-6.55%	\$1,606,983	\$1,665,036	(\$58,053)	96.51%
August 2024	\$2,049,951	(\$153,375)	-7.48%	\$1,896,576	\$1,897,978	(\$1,402)	99.92%
September 2024	\$2,305,968	(\$757,899)	-32.86%	\$1,548,069	\$1,435,623	\$112,446	107.83%
October 2024	\$1,871,784	(\$141,940)	-7.58%	\$1,729,844	\$1,792,863	(\$63,019)	96.48%
November 2024	\$2,210,061	(\$776,404)	-35.13%	\$1,433,657	\$1,511,902	(\$78,245)	94.82%
December 2024	\$1,909,361	(\$647,805)	-33.92%	\$1,261,556	\$1,309,113	(\$47,557)	96.36%
January 2025	\$1,339,798	(\$82,546)	-6.16%	\$1,257,252	\$1,282,560	(\$25,308)	98.02%
February 2025	\$1,560,532	(\$147,649)	-9.46%	\$1,412,882	\$1,490,903	(\$78,021)	94.76%
March 2025	\$1,474,632	(\$81,678)	-5.53%	\$1,392,954	\$1,429,442	(\$36,488)	97.44%
April 2025	\$1,479,853	(\$78,969)	-5.33%	\$1,400,884	\$1,444,413	(\$43,530)	96.98%
May 2025	\$1,601,699	(\$82,318)	-5.13%	\$1,519,381	\$1,556,943	(\$37,561)	97.58%
June 2025	\$1,368,689	(\$24,869)	-1.81%	\$1,343,820	\$1,346,617	(\$2,798)	99.79%
Cumulative Totals	\$39,310,859	(\$3,838,132)	-9.76%	\$35,472,728	\$36,207,394	(\$734,666)	97.97%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-1.03%



Envolve Dental

Table 3 — LHCC Envolve Dental

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$736,285	(\$47,993)	-6.51%	\$688,291	\$691,733	(\$3,442)	99.50%
August 2023	\$855,648	(\$58,560)	-6.84%	\$797,088	\$802,812	(\$5,725)	99.28%
September 2023	\$822,341	(\$76,952)	-9.35%	\$745,389	\$750,614	(\$5,225)	99.30%
October 2023	\$841,630	(\$65,030)	-7.72%	\$776,600	\$789,034	(\$12,434)	98.42%
November 2023	\$800,202	(\$60,166)	-7.51%	\$740,036	\$702,572	\$37,464	105.33%
December 2023	\$647,813	(\$25,452)	-3.92%	\$622,361	\$625,140	(\$2,778)	99.55%
January 2024	\$262,891	(\$12,894)	-4.90%	\$249,997	\$231,175	\$18,822	108.14%
February 2024	\$35,518	(\$5,629)	-15.84%	\$29,889	\$29,291	\$598	102.04%
March 2024	\$11,902	(\$234)	-1.96%	\$11,668	\$9,736	\$1,931	119.83%
April 2024	\$12,831	(\$421)	-3.28%	\$12,410	\$11,491	\$919	107.99%
May 2024	\$5,808	\$0	0.00%	\$5,808	\$5,507	\$300	105.45%
June 2024	\$4,402	\$0	0.00%	\$4,402	\$3,940	\$462	111.73%
July 2024	\$1,613	\$0	0.00%	\$1,613	\$1,485	\$128	108.62%
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$5,038,884	(\$353,332)	-7.01%	\$4,685,552	\$4,654,530	\$31,022	100.66%
100% Limited Cumulative Total				\$4,654,530	\$4,654,530	\$0	100.00%
Minimum Completeness (%)							99.00%
Non-Compliant							0.66%



Veyo (NEMT)

Table 4 — LHCC Veyo (NEMT)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$3,352,135	(\$41,418)	-1%	\$3,310,716	\$3,318,612	(\$7,895)	99.76%
August 2023	\$4,132,969	(\$68,279)	-2%	\$4,064,690	\$4,079,627	(\$14,937)	99.63%
September 2023	\$2,990,729	(\$18,442)	-1%	\$2,972,287	\$2,983,948	(\$11,660)	99.60%
October 2023	\$3,064,979	(\$926,808)	-30%	\$2,138,171	\$2,138,779	(\$608)	99.97%
November 2023	\$3,544,773	(\$41,206)	-1.16%	\$3,503,567	\$3,518,144	(\$14,577)	99.58%
December 2023	\$2,191,076	(\$38,904)	-1.77%	\$2,152,172	\$2,180,205	(\$28,033)	98.71%
January 2024	\$2,305,501	(\$54,098)	-2.34%	\$2,251,403	\$2,246,686	\$4,718	100.20%
February 2024	\$3,003,332	(\$83,669)	-2.78%	\$2,919,662	\$2,912,875	\$6,787	100.23%
March 2024	\$2,490,950	(\$29,809)	-1.19%	\$2,461,142	\$2,446,928	\$14,214	100.58%
April 2024	\$2,515,986	(\$59,738)	-2.37%	\$2,456,249	\$2,464,324	(\$8,075)	99.67%
May 2024	\$3,287,016	(\$82,962)	-2.52%	\$3,204,054	\$3,179,921	\$24,134	100.75%
June 2024	\$3,032,645	(\$78,215)	-2.57%	\$2,954,430	\$2,985,390	(\$30,960)	98.96%
July 2024	\$2,743,436	(\$81,288)	-2.96%	\$2,662,148	\$2,680,421	(\$18,273)	99.31%
August 2024	\$3,192,366	(\$121,309)	-3.79%	\$3,071,058	\$3,052,166	\$18,892	100.61%
September 2024	\$2,861,491	(\$645,285)	-22.55%	\$2,216,206	\$2,086,919	\$129,287	106.19%
October 2024	\$3,575,026	(\$84,719)	-2.36%	\$3,490,307	\$3,431,205	\$59,102	101.72%
November 2024	\$2,674,215	(\$63,733)	-2.38%	\$2,610,483	\$2,558,545	\$51,938	102.02%
December 2024	\$2,582,604	(\$78,537)	-3.04%	\$2,504,067	\$2,583,716	(\$79,649)	96.91%
January 2025	\$2,602,573	(\$49,955)	-1.91%	\$2,552,618	\$2,576,188	(\$23,570)	99.08%
February 2025	\$2,331,164	(\$68,861)	-2.95%	\$2,262,303	\$2,324,080	(\$61,777)	97.34%
March 2025	\$2,298,966	(\$74,856)	-3.25%	\$2,224,110	\$2,349,590	(\$125,479)	94.65%
April 2025	\$2,039,293	(\$100,140)	-4.91%	\$1,939,153	\$1,997,692	(\$58,539)	97.06%
May 2025	\$1,855,456	(\$48,523)	-2.61%	\$1,806,933	\$1,856,666	(\$49,733)	97.32%
June 2025	\$185,678	(\$9,819)	-5.28%	\$175,859	\$187,562	(\$11,703)	93.76%
Cumulative Totals	\$64,854,360	(\$2,950,571)	-4.54%	\$61,903,788	\$62,140,187	(\$236,399)	99.61%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							N/A



MediTrans (NEMT)

Table 5 — LHCC MediTrans (NEMT)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completi on Percentage
July 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2025	\$583,127	(\$14,090)	-2.41%	\$569,037	\$583,082	(\$14,045)	97.59%
June 2025	\$1,079,269	(\$245,871)	-22.78%	\$833,398	\$1,479,699	(\$646,302)	56.32%
Cumulative Totals	\$1,662,396	(\$259,962)	-15.63%	\$1,402,435	\$2,062,782	(\$660,347)	67.98%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-31.02%



CVS Health (Pharmacy)

Table 6 — LHCC CVS Health (Pharmacy)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$64,701,877	(\$973,633)	-1.50%	\$63,728,244	\$64,037,376	(\$309,132)	99.51%
August 2023	\$513,468,764	(\$407,318,670)	-79.32%	\$106,150,095	\$84,058,214	\$22,091,881	126.28%
September 2023	\$62,523,229	(\$1,045,050)	-1.67%	\$61,478,179	\$61,619,717	(\$141,539)	99.77%
October 2023	\$65,730,354	(\$366,594)	-0.55%	\$65,363,760	\$65,111,253	\$252,507	100.38%
November 2023	\$22,554,480	(\$170,022)	-0.75%	\$22,384,458	\$20,875,434	\$1,509,025	107.22%
December 2023	\$50,301	(\$2)	0.00%	\$50,299	(\$33,991)	\$84,290	-147.97%
January 2024	\$31,077	(\$828)	-2.66%	\$30,249	(\$31,938)	\$62,187	-94.71%
February 2024	(\$3,129)	\$0	0.00%	(\$3,129)	(\$6,260)	\$3,130	49.99%
March 2024	\$247,246	(\$231,852)	-93.77%	\$15,394	(\$7,305)	\$22,699	-210.74%
April 2024	\$281,116	(\$71,786)	-25.53%	\$209,330	(\$1,543)	\$210,872	-13570.11%
May 2024	\$0	\$0	N/A	\$0	(\$5,564)	\$5,564	0.00%
June 2024	\$0	\$0	N/A	\$0	(\$139,650)	\$139,650	0.00%
July 2024	\$0	\$0	N/A	\$0	\$146	(\$146)	0.00%
August 2024	\$0	\$0	N/A	\$0	(\$71)	\$71	0.00%
September 2024	\$0	\$0	N/A	\$0	(\$1,939)	\$1,939	0.00%
October 2024	\$0	\$0	N/A	\$0	\$8,313	(\$8,313)	0.00%
November 2024	\$0	\$0	N/A	\$0	\$288	(\$288)	0.00%
December 2024	\$0	\$0	N/A	\$0	(\$1,853)	\$1,853	0.00%
January 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$729,585,316	(\$410,178,438)	-56.22%	\$319,406,878	\$295,480,628	\$23,926,251	108.09%
100% Limited Cumulative Total				\$295,480,628	\$295,480,628	\$0	100.00%
Minimum Completeness (%)							99.00%
Non-Compliant							8.09%



Prime Therapeutics (Pharmacy)

Table 7 — LHCC Prime Therapeutics (Pharmacy)							
Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2023	\$61,001,492	(\$2,058,279)	-3.37%	\$58,943,213	\$63,000,862	(\$4,057,649)	93.55%
December 2023	\$67,087,046	(\$1,763,198)	-2.62%	\$65,323,849	\$65,494,803	(\$170,955)	99.73%
January 2024	\$74,244,370	(\$1,336,626)	-1.80%	\$72,907,744	\$74,088,939	(\$1,181,195)	98.40%
February 2024	\$66,917,780	(\$940,926)	-1.40%	\$65,976,854	\$63,963,683	\$2,013,170	103.14%
March 2024	\$64,858,549	(\$677,523)	-1.04%	\$64,181,026	\$64,847,226	(\$666,200)	98.97%
April 2024	\$77,106,849	(\$891,875)	-1.15%	\$76,214,974	\$77,957,472	(\$1,742,498)	97.76%
May 2024	\$63,628,174	(\$875,418)	-1.37%	\$62,752,756	\$63,749,883	(\$997,127)	98.43%
June 2024	\$74,417,601	(\$11,560,574)	-15.53%	\$62,857,027	\$62,029,908	\$827,119	101.33%
July 2024	\$77,522,864	(\$721,105)	-0.93%	\$76,801,759	\$76,205,504	\$596,255	100.78%
August 2024	\$61,745,235	(\$737,366)	-1.19%	\$61,007,870	\$60,546,561	\$461,309	100.76%
September 2024	\$57,793,774	(\$217,744)	-0.37%	\$57,576,030	\$58,042,044	(\$466,014)	99.19%
October 2024	\$75,180,236	(\$223,083)	-0.29%	\$74,957,153	\$75,165,009	(\$207,856)	99.72%
November 2024	\$47,203,953	(\$535,233)	-1.13%	\$46,668,720	\$59,676,841	(\$13,008,122)	78.20%
December 2024	\$75,553,756	(\$612,631)	-0.81%	\$74,941,125	\$73,883,516	\$1,057,609	101.43%
January 2025	\$53,374,105	(\$464,013)	-0.86%	\$52,910,092	\$52,776,410	\$133,682	100.25%
February 2025	\$54,450,223	(\$438,386)	-0.80%	\$54,011,836	\$55,430,490	(\$1,418,654)	97.44%
March 2025	\$58,114,433	(\$612,988)	-1.05%	\$57,501,445	\$57,770,684	(\$269,240)	99.53%
April 2025	\$59,856,158	(\$751,450)	-1.25%	\$59,104,709	\$72,708,770	(\$13,604,061)	81.28%
May 2025	\$58,063,581	(\$413,755)	-0.71%	\$57,649,826	\$56,613,215	\$1,036,611	101.83%
June 2025	\$54,757,446	(\$386,217)	-0.70%	\$54,371,229	\$55,136,092	(\$764,862)	98.61%
Cumulative Totals	\$1,282,877,626	(\$26,218,390)	-2.04%	\$1,256,659,236	\$1,289,087,912	(\$32,428,676)	97.48%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							97.00%
Non-Compliant							N/A



Non-Vendor

Table 8 — LHCC Non-Vendor

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$140,391,445	(\$32,077,973)	-22.84%	\$108,313,472	\$110,172,949	(\$1,859,476)	98.31%
August 2023	\$181,612,074	(\$47,038,189)	-25.90%	\$134,573,885	\$135,907,159	(\$1,333,274)	99.01%
September 2023	\$155,052,800	(\$25,358,822)	-16.35%	\$129,693,978	\$130,969,787	(\$1,275,808)	99.02%
October 2023	\$148,049,230	(\$19,662,886)	-13.28%	\$128,386,344	\$128,326,344	\$60,000	100.04%
November 2023	\$138,618,165	(\$23,418,973)	-16.89%	\$115,199,192	\$117,346,138	(\$2,146,946)	98.17%
December 2023	\$151,937,331	(\$30,942,123)	-20.36%	\$120,995,208	\$123,656,841	(\$2,661,633)	97.84%
January 2024	\$153,693,469	(\$31,966,579)	-20.79%	\$121,726,890	\$127,385,216	(\$5,658,326)	95.55%
February 2024	\$134,908,708	(\$28,270,972)	-20.95%	\$106,637,735	\$109,945,447	(\$3,307,712)	96.99%
March 2024	\$135,536,988	(\$26,126,228)	-19.27%	\$109,410,760	\$113,985,213	(\$4,574,453)	95.98%
April 2024	\$137,003,202	(\$19,574,517)	-14.28%	\$117,428,686	\$122,047,288	(\$4,618,602)	96.21%
May 2024	\$138,748,523	(\$27,294,879)	-19.67%	\$111,453,644	\$114,729,525	(\$3,275,881)	97.14%
June 2024	\$142,610,538	(\$24,255,851)	-17.00%	\$118,354,687	\$121,409,561	(\$3,054,874)	97.48%
July 2024	\$158,614,711	(\$34,839,638)	-21.96%	\$123,775,072	\$125,524,233	(\$1,749,161)	98.60%
August 2024	\$141,867,402	(\$27,922,764)	-19.68%	\$113,944,639	\$116,258,900	(\$2,314,261)	98.00%
September 2024	\$139,668,684	(\$28,836,834)	-20.64%	\$110,831,850	\$112,996,583	(\$2,164,733)	98.08%
October 2024	\$153,796,425	(\$29,369,026)	-19.09%	\$124,427,399	\$128,325,120	(\$3,897,722)	96.96%
November 2024	\$154,072,549	(\$34,780,109)	-22.57%	\$119,292,439	\$124,686,270	(\$5,393,830)	95.67%
December 2024	\$169,573,173	(\$46,608,822)	-27.48%	\$122,964,352	\$126,831,213	(\$3,866,861)	96.95%
January 2025	\$124,425,730	(\$16,039,380)	-12.89%	\$108,386,349	\$109,589,532	(\$1,203,183)	98.90%
February 2025	\$150,930,626	(\$46,682,375)	-30.92%	\$104,248,252	\$107,794,675	(\$3,546,423)	96.71%
March 2025	\$114,090,234	(\$15,891,163)	-13.92%	\$98,199,071	\$104,102,760	(\$5,903,689)	94.32%
April 2025	\$133,564,128	(\$13,043,487)	-9.76%	\$120,520,641	\$125,625,096	(\$5,104,455)	95.93%
May 2025	\$115,232,516	(\$10,064,556)	-8.73%	\$105,167,959	\$109,942,093	(\$4,774,134)	95.65%
June 2025	\$103,346,703	(\$7,680,879)	-7.43%	\$95,665,824	\$105,491,439	(\$9,825,615)	90.68%
Cumulative Totals	\$3,417,345,354	(\$647,747,027)	-18.95%	\$2,769,598,328	\$2,853,049,380	(\$83,451,053)	97.07%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-1.93%



Appendix A: VAS Monthly Tables

Entire Plan VAS

Table 1V — LHCC VAS (Entire Plan)							
Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$1,373,221	(\$68,949)	-5.02%	\$1,304,273	\$1,307,355	(\$3,083)	99.76%
August 2023	\$1,728,895	(\$130,924)	-7.57%	\$1,597,971	\$1,608,337	(\$10,366)	99.35%
September 2023	\$1,500,976	(\$106,840)	-7.11%	\$1,394,135	\$1,401,624	(\$7,489)	99.46%
October 2023	\$1,486,328	(\$104,928)	-7.05%	\$1,381,400	\$1,377,536	\$3,864	100.28%
November 2023	\$1,455,093	(\$82,536)	-5.67%	\$1,372,558	\$1,314,109	\$58,449	104.44%
December 2023	\$1,135,015	(\$38,026)	-3.35%	\$1,096,988	\$1,090,844	\$6,145	100.56%
January 2024	\$823,130	(\$39,488)	-4.79%	\$783,642	\$752,145	\$31,496	104.18%
February 2024	\$729,739	(\$28,610)	-3.92%	\$701,130	\$690,322	\$10,808	101.56%
March 2024	\$726,099	(\$37,220)	-5.12%	\$688,879	\$677,795	\$11,084	101.63%
April 2024	\$683,808	(\$57,624)	-8.42%	\$626,184	\$636,703	(\$10,519)	98.34%
May 2024	\$776,820	(\$76,723)	-9.87%	\$700,097	\$708,432	(\$8,334)	98.82%
June 2024	\$626,229	(\$72,246)	-11.53%	\$553,983	\$568,420	(\$14,437)	97.46%
July 2024	\$686,657	(\$78,955)	-11.49%	\$607,702	\$625,379	(\$17,677)	97.17%
August 2024	\$660,019	(\$58,150)	-8.81%	\$601,868	\$619,932	(\$18,063)	97.08%
September 2024	\$592,288	(\$140,022)	-23.64%	\$452,266	\$526,422	(\$74,156)	85.91%
October 2024	\$723,169	(\$71,029)	-9.82%	\$652,140	\$685,416	(\$33,276)	95.14%
November 2024	\$763,444	(\$235,956)	-30.90%	\$527,488	\$567,067	(\$39,580)	93.02%
December 2024	\$650,874	(\$207,664)	-31.90%	\$443,211	\$471,638	(\$28,427)	93.97%
January 2025	\$534,940	(\$32,216)	-6.02%	\$502,723	\$510,886	(\$8,163)	98.40%
February 2025	\$689,736	(\$83,682)	-12.13%	\$606,054	\$638,452	(\$32,398)	94.92%
March 2025	\$604,444	(\$41,051)	-6.79%	\$563,392	\$579,568	(\$16,175)	97.20%
April 2025	\$615,911	(\$35,318)	-5.73%	\$580,593	\$603,268	(\$22,674)	96.24%
May 2025	\$619,416	(\$27,790)	-4.48%	\$591,626	\$606,475	(\$14,849)	97.55%
June 2025	\$523,051	(\$17,291)	-3.30%	\$505,760	\$506,659	(\$900)	99.82%
Cumulative Totals	\$20,709,302	(\$1,873,239)	-9.04%	\$18,836,063	\$19,074,784	(\$238,721)	98.74%
100% Limited Cumulative Total				\$18,725,546	\$19,074,784	(\$349,238)	98.16%
Minimum Completeness (%)							99.00%
Non-Compliant							-0.26%



Engolve Vision VAS

Table 2V — LHCC Engolve Vision VAS

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$409,053	(\$8,594)	-2.10%	\$400,459	\$400,449	\$10	100.00%
August 2023	\$524,404	(\$11,220)	-2.13%	\$513,184	\$514,929	(\$1,745)	99.66%
September 2023	\$432,399	(\$9,530)	-2.20%	\$422,869	\$426,568	(\$3,699)	99.13%
October 2023	\$443,736	(\$9,080)	-2.04%	\$434,656	\$433,005	\$1,651	100.38%
November 2023	\$467,275	(\$11,172)	-2.39%	\$456,104	\$459,736	(\$3,633)	99.20%
December 2023	\$327,248	(\$4,089)	-1.24%	\$323,159	\$330,946	(\$7,787)	97.64%
January 2024	\$415,840	(\$12,972)	-3.11%	\$402,868	\$406,513	(\$3,645)	99.10%
February 2024	\$540,427	(\$14,204)	-2.62%	\$526,223	\$528,304	(\$2,081)	99.60%
March 2024	\$574,515	(\$26,529)	-4.61%	\$547,985	\$550,392	(\$2,407)	99.56%
April 2024	\$514,492	(\$47,229)	-9.17%	\$467,263	\$482,227	(\$14,964)	96.89%
May 2024	\$594,381	(\$50,900)	-8.56%	\$543,480	\$557,982	(\$14,502)	97.40%
June 2024	\$489,388	(\$48,072)	-9.82%	\$441,316	\$451,650	(\$10,334)	97.71%
July 2024	\$520,068	(\$41,160)	-7.91%	\$478,908	\$489,703	(\$10,795)	97.79%
August 2024	\$515,691	(\$32,100)	-6.22%	\$483,590	\$489,330	(\$5,739)	98.82%
September 2024	\$406,896	(\$84,435)	-20.75%	\$322,461	\$379,165	(\$56,704)	85.04%
October 2024	\$540,670	(\$37,648)	-6.96%	\$503,022	\$516,838	(\$13,816)	97.32%
November 2024	\$600,369	(\$205,162)	-34.17%	\$395,207	\$413,679	(\$18,472)	95.53%
December 2024	\$507,935	(\$174,832)	-34.42%	\$333,103	\$343,843	(\$10,740)	96.87%
January 2025	\$419,678	(\$14,289)	-3.40%	\$405,389	\$409,695	(\$4,306)	98.94%
February 2025	\$525,399	(\$43,437)	-8.26%	\$481,962	\$506,583	(\$24,621)	95.13%
March 2025	\$477,223	(\$16,251)	-3.40%	\$460,972	\$473,385	(\$12,413)	97.37%
April 2025	\$489,750	(\$19,488)	-3.97%	\$470,261	\$486,378	(\$16,117)	96.68%
May 2025	\$515,095	(\$16,199)	-3.14%	\$498,897	\$509,569	(\$10,672)	97.90%
June 2025	\$396,792	(\$4,751)	-1.19%	\$392,040	\$390,676	\$1,364	100.34%
Cumulative Totals	\$11,648,723	(\$943,343)	-8.09%	\$10,705,379	\$10,951,545	(\$246,166)	97.75%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-1.25%



Engolve Dental VAS

Table 3V — LHCC Engolve Dental VAS

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$736,285	(\$47,993)	-6.51%	\$688,291	\$691,733	(\$3,442)	99.50%
August 2023	\$855,648	(\$58,560)	-6.84%	\$797,088	\$802,812	(\$5,725)	99.28%
September 2023	\$822,341	(\$76,952)	-9.35%	\$745,389	\$750,614	(\$5,225)	99.30%
October 2023	\$841,630	(\$65,030)	-7.72%	\$776,600	\$789,034	(\$12,434)	98.42%
November 2023	\$800,202	(\$60,166)	-7.51%	\$740,036	\$702,572	\$37,464	105.33%
December 2023	\$647,813	(\$25,452)	-3.92%	\$622,361	\$625,140	(\$2,778)	99.55%
January 2024	\$262,891	(\$12,894)	-4.90%	\$249,997	\$231,175	\$18,822	108.14%
February 2024	\$35,518	(\$5,629)	-15.84%	\$29,889	\$29,291	\$598	102.04%
March 2024	\$11,902	(\$234)	-1.96%	\$11,668	\$9,736	\$1,931	119.83%
April 2024	\$12,831	(\$421)	-3.28%	\$12,410	\$11,491	\$919	107.99%
May 2024	\$5,808	\$0	0.00%	\$5,808	\$5,507	\$300	105.45%
June 2024	\$4,402	\$0	0.00%	\$4,402	\$3,940	\$462	111.73%
July 2024	\$1,613	\$0	0.00%	\$1,613	\$1,485	\$128	108.62%
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$5,038,884	(\$353,332)	-7.01%	\$4,685,552	\$4,654,530	\$31,022	100.66%
100% Limited Cumulative Total				\$4,654,530	\$4,654,530	\$0	100.00%
Minimum Completeness (%)							99.00%
Non-Compliant							0.66%



Veyo (NEMT) VAS

Table 4V — LHCC Veyo VAS (NEMT)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$141,839	(\$3,957)	-2.78%	\$137,882	\$141,971	(\$4,089)	97.11%
August 2023	\$196,828	(\$6,849)	-3.47%	\$189,979	\$195,760	(\$5,781)	97.04%
September 2023	\$146,252	(\$6,647)	-4.54%	\$139,605	\$141,128	(\$1,522)	98.92%
October 2023	\$88,808	(\$22,386)	-25.20%	\$66,422	\$58,815	\$7,607	112.93%
November 2023	\$88,673	(\$5,130)	-5.78%	\$83,542	\$65,010	\$18,532	128.50%
December 2023	\$60,937	(\$3,293)	-5.40%	\$57,644	\$45,135	\$12,509	127.71%
January 2024	\$48,586	(\$1,897)	-3.90%	\$46,689	\$35,493	\$11,196	131.54%
February 2024	\$67,481	(\$1,360)	-2.01%	\$66,121	\$56,298	\$9,824	117.44%
March 2024	\$59,371	(\$1,762)	-2.96%	\$57,609	\$47,570	\$10,039	121.10%
April 2024	\$56,019	(\$2,899)	-5.17%	\$53,120	\$45,740	\$7,380	116.13%
May 2024	\$81,154	(\$16,218)	-19.98%	\$64,937	\$62,647	\$2,289	103.65%
June 2024	\$55,401	(\$16,690)	-30.12%	\$38,711	\$46,091	(\$7,380)	83.98%
July 2024	\$61,620	(\$20,843)	-33.82%	\$40,777	\$48,965	(\$8,188)	83.27%
August 2024	\$65,066	(\$20,729)	-31.85%	\$44,337	\$55,231	(\$10,894)	80.27%
September 2024	\$70,036	(\$34,788)	-49.67%	\$35,248	\$52,380	(\$17,133)	67.29%
October 2024	\$79,386	(\$27,369)	-34.47%	\$52,017	\$69,462	(\$17,445)	74.88%
November 2024	\$56,639	(\$17,200)	-30.36%	\$39,439	\$54,542	(\$15,104)	72.30%
December 2024	\$50,011	(\$15,860)	-31.71%	\$34,151	\$50,445	(\$16,294)	67.70%
January 2025	\$51,478	(\$14,816)	-28.78%	\$36,662	\$51,338	(\$14,676)	71.41%
February 2025	\$47,493	(\$13,951)	-29.37%	\$33,542	\$47,287	(\$13,745)	70.93%
March 2025	\$47,682	(\$15,836)	-33.21%	\$31,846	\$49,896	(\$18,050)	63.82%
April 2025	\$40,300	(\$14,144)	-35.09%	\$26,156	\$39,796	(\$13,641)	65.72%
May 2025	\$27,883	(\$10,311)	-36.97%	\$17,572	\$27,960	(\$10,388)	62.84%
June 2025	\$2,194	(\$905)	-41.22%	\$1,290	\$2,194	(\$905)	58.77%
Cumulative Totals	\$1,691,137	(\$295,839)	-17.49%	\$1,395,298	\$1,491,156	(\$95,858)	93.57%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-5.43%



MediTrans (NEMT) VAS

Table 5V — LHCC MediTrans VAS (NEMT)

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completi on Percentage
July 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2025	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2025	\$9,674	(\$54)	-0.55%	\$9,620	\$9,674	(\$54)	99.44%
June 2025	\$41,809	(\$10,888)	-26.04%	\$30,921	\$38,081	(\$7,160)	81.19%
Cumulative Totals	\$51,483	(\$10,942)	-21.25%	\$40,540	\$47,754	(\$7,214)	84.89%
100% Limited Cumulative Total							N/A
Minimum Completeness (%)							99.00%
Non-Compliant							-14.11%



Non-Vendor VAS

Table 6V — LHCC Non-Vendor VAS

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
July 2023	\$86,045	(\$8,404)	-9.76%	\$77,641	\$73,202	\$4,439	106.06%
August 2023	\$152,016	(\$54,295)	-35.71%	\$97,720	\$94,836	\$2,885	103.04%
September 2023	\$99,983	(\$13,712)	-13.71%	\$86,272	\$83,315	\$2,957	103.54%
October 2023	\$112,154	(\$8,432)	-7.51%	\$103,722	\$96,682	\$7,040	107.28%
November 2023	\$98,943	(\$6,067)	-6.13%	\$92,876	\$86,790	\$6,086	107.01%
December 2023	\$99,016	(\$5,191)	-5.24%	\$93,825	\$89,623	\$4,201	104.68%
January 2024	\$95,813	(\$11,725)	-12.23%	\$84,087	\$78,964	\$5,123	106.48%
February 2024	\$86,313	(\$7,417)	-8.59%	\$78,897	\$76,430	\$2,467	103.22%
March 2024	\$80,312	(\$8,694)	-10.82%	\$71,618	\$70,097	\$1,520	102.16%
April 2024	\$100,466	(\$7,075)	-7.04%	\$93,391	\$97,246	(\$3,855)	96.03%
May 2024	\$95,478	(\$9,605)	-10.05%	\$85,873	\$82,295	\$3,578	104.34%
June 2024	\$77,038	(\$7,484)	-9.71%	\$69,554	\$66,739	\$2,815	104.21%
July 2024	\$103,356	(\$16,952)	-16.40%	\$86,404	\$85,227	\$1,177	101.38%
August 2024	\$79,261	(\$5,321)	-6.71%	\$73,941	\$75,371	(\$1,430)	98.10%
September 2024	\$115,356	(\$20,799)	-18.03%	\$94,556	\$94,876	(\$320)	99.66%
October 2024	\$103,113	(\$6,013)	-5.83%	\$97,100	\$99,116	(\$2,015)	97.96%
November 2024	\$106,436	(\$13,594)	-12.77%	\$92,842	\$98,846	(\$6,004)	93.92%
December 2024	\$92,928	(\$16,972)	-18.26%	\$75,956	\$77,349	(\$1,393)	98.19%
January 2025	\$63,784	(\$3,111)	-4.87%	\$60,673	\$49,853	\$10,820	121.70%
February 2025	\$116,844	(\$26,294)	-22.50%	\$90,549	\$84,581	\$5,968	107.05%
March 2025	\$79,539	(\$8,965)	-11.27%	\$70,574	\$56,287	\$14,288	125.38%
April 2025	\$85,862	(\$1,686)	-1.96%	\$84,176	\$77,093	\$7,083	109.18%
May 2025	\$66,764	(\$1,226)	-1.83%	\$65,538	\$59,273	\$6,266	110.57%
June 2025	\$82,256	(\$747)	-0.90%	\$81,509	\$75,708	\$5,801	107.66%
Cumulative Totals	\$2,279,076	(\$269,782)	-11.83%	\$2,009,294	\$1,929,799	\$79,495	104.11%
100% Limited Cumulative Total				\$1,929,799	\$1,929,799	\$0	100.00%
Minimum Completeness (%)							99.00%
Non-Compliant							4.11%



Appendix B: Definitions and Acronyms

The following terms are used throughout this document:

- **Cash Disbursement Journal (CDJ)** – A record of payments from an MCO or delegated vendor to service providers for a given month as reported by the MCO to the Louisiana Department of Health (LDH).
- **DXC Technology (DXC)** – State fiscal agent contractor prior to October 1, 2020. In 2020, DXC was sold to Veritas Capital and ultimately formed a new company, Gainwell Technologies.
- **Fiscal Agent Contractor (FAC)** – A contractor selected to design, develop and maintain the Medicaid Management Information System (MMIS); Gainwell is the current FAC.
- **Gainwell Technologies (Gainwell)** – Current State fiscal agent contractor. Formerly known as DXC Technology.
- **Healthy Louisiana** – The name of Louisiana’s Medicaid managed care program as of May 2016.
- **Louisiana Department of Health (LDH)** – The agency in charge of overseeing the health services for the citizens of the state of Louisiana.
- **Managed Care Organization (MCO)** – A private organization that has entered into a risk-based contractual arrangement with LDH to obtain and finance care for enrolled Medicaid or Louisiana Children’s Health Insurance Program (LaCHIP) members. MCOs receive a capitation, or per member per month (PMPM), payment from LDH for each enrolled member. During the reporting period, six MCOs were operating in Louisiana. They are Healthy Blue – formerly Amerigroup Louisiana, Inc., AmeriHealth Caritas Louisiana (ACLA), Louisiana Healthcare Connections (LHCC), Aetna Better Health of Louisiana (Aetna), UnitedHealthcare Community Plan (UHC), and Humana Healthy Horizons in Louisiana (Humana).
- **Medicaid Management Information System (MMIS)** – The claims and encounter processing system used by the FAC. MCO submitted encounters are loaded into this system and assigned a unique claim identifier.
- **Value-Added Services (VAS)** – A covered service provided by the MCO to its members that is currently a non-covered service in the state’s fee-for-service plan, for which the MCO received no additional capitated payment. Also known as Expanded Services.



The following terms are used in the monthly tables throughout this document:

- **100% Limited Completion** - When an individual vendor's cumulative completion percentage exceeds 100 percent, the encounter total is decreased by the variance between the encounter and cash disbursement journal payment amounts. This results in a limited cumulative completion percentage of 100%. For the entire plan, (Tables 1 and 1V), the limited cumulative completion percentage is calculated using the adjusted encounter amounts of all limited vendor and non-vendor results. This adjustment is to ensure that the entire plan completion percentage is not over-stated.
- **CDJ Monthly Reported Total** – The sum of all payments from an MCO or delegated vendor to service providers for the reconciliation period reported in the Cash Disbursement Journal (CDJ).
- **Monthly Completion Percentage** – The “Monthly Encounter Net Total” divided by “CDJ Monthly Reported Total.”
- **Monthly Encounter Net Total** – The difference between the “Monthly Encounter Total (FAC Reported)” and “Monthly Encounter Total (Adjustments).”
- **Monthly Encounter Total (Adjustments)** – Total paid amount of encounters identified as denied, calculated void or potential duplicate.
 - **State System Denied Encounter** – A submitted encounter that is paid by the plan but is denied by the Fiscal Agent Contractor (FAC) due to MMIS Claims Subsystem edits.
 - **Health Plan Denied Encounter** – A submitted encounter that is denied by the plan. This denied encounter is indicated by a value of ‘D’ in the second position of the MCO ICN submitted by the plan.
 - **Calculated Voids** – A pair of paid encounters having the same base patient account number or plan internal control number (ICN) if applicable. One of the encounters may appear to be a replacement of the other without a corresponding void encounter transaction being present. In this case, an adjustment is made to account for the missing void transaction. The magnitude of this adjustment depends upon the plans’ response to a listing of potential calculated void encounters.
 - **Duplicate Encounters** – A pair of paid encounters having identically-billed fields that appear to be duplicates of one another. One of these encounters may be excluded from the analysis depending upon the plans’ response to a listing of potential duplicate encounters.
- **Monthly Encounter Total (FAC Reported)** – The sum of all paid amounts on encounters submitted to the MMIS.
- **Monthly Variance** – The difference between the “Monthly Encounter Net Total” and the “CDJ Monthly Reported Total.”
- **Percentage of Encounters Adjusted** – The “Monthly Encounter Total (Adjustments)” divided by “Monthly Encounter Total (FAC Reported).”

Appendix C: Analysis

Encounters from institutional, medical and pharmacy claim types were combined on like data fields. We analyzed the line reported information of each encounter to capture the amount paid on the entire claim. Encounter totals were calculated by summarizing the data by the MCO paid date, MCO identification number (ID) and specific delegated vendor criteria. MCO submitted cash disbursements were summarized by paid date, MCO ID and specific delegated vendor criteria to create a matching table. These matching tables were combined using common fields between the tables and were used to produce the results.

Based on criteria provided by the MCO, we identified LHCC encounters as follows:

Active Vendors			
Vendor Type	Vendor Name	Identified By	Notes
Vision Services	Envolve Vision (formerly OptiCare)	Characters 3 and 4 of Plan ICN contain "OC"	
Dental Services	Envolve Dental	Characters 3 and 4 of Plan ICN contain "DH"	Vendor no longer active as of January 1, 2024
Non-Emergency Medical Transportation (NEMT)	MediTrans	Characters 3 and 4 of Plan ICN contain "MT"	
Pharmacy Benefits	Prime Therapeutics	Claim type code of '12' Characters 3 and 4 of Plan ICN contain "PB" Dates of service beginning on October 28, 2023	Formerly known as Magellan Rx prior to January 2025 report
Non-Vendor	LHCC	All other plan submitted encounters	

Inactive Vendors			
Vendor Type	Vendor Name	Identified By	Notes
Pharmacy Benefits	Envolve Pharmacy Solutions (formerly US Script)	Claim type code of '12' and Dates of service prior to September 1, 2017	Replaced by CVS Health – Effective September 1, 2017
Non-Emergency Medical Transportation (NEMT)	ModivCare (formerly LogistiCare)	Characters 3 and 4 of Plan ICN contain "LC"	Replaced by Veyo – Effective May 1, 2021
Pharmacy Benefits	CVS Health	Claim type code of '12' and Dates of service beginning on September 1, 2017	Replaced by Magellan Rx – Effective October 28, 2023
Non-Emergency Medical Transportation (NEMT)	Veyo	Characters 3 and 4 of Plan ICN contain "VE"	Replaced by MediTrans – Effective May 1, 2025



Appendix D: Data Analysis Assumptions

1. This analysis is performed on encounter data that was submitted by the MCOs to the FAC and loaded into the FAC MMIS. Encounters submitted by any MCO that were rejected by the FAC for errors in submission or other reasons are not transmitted to Myers and Stauffer LC.
2. For the purposes of this study, the payment amounts associated with denied encounters are identified as zero dollars in the encounter reconciliation analysis since they bear no impact on cash disbursements.
3. A voiding encounter has the same paid date as the original/voided encounter, which may differ from when the void or adjustment occurred. Therefore, the voiding encounters were coded to match the adjustment claim's paid date to allow for the proper matching of cash disbursements that occurred due to these void transactions. However, we were unable to reallocate the void encounters in which there was not an associated adjustment claim.
4. CDJ and encounter payments are analyzed to ensure that positive and negative payments correspond to the record's transaction type. For example, a void should have a negative amount. Additionally, the payment's amount on void and back-out encounters should match the amount on the encounter being adjusted. If detected, the payment is adjusted to the appropriate sign or amount.
5. We instructed the MCOs to exclude referral fees, management fees, and other non-encounter related fees from the CDJ data that is submitted to Myers and Stauffer LC. We reviewed the CDJs for these payments and removed them from the analysis when they were identified.
6. Separately itemized interest expenses are excluded from the CDJ and encounter totals when the interest amounts are included in the MCO paid amounts on the encounters and/or CDJ transactions.
7. Due to rounding, the sum of the displayed percentages in this report may not add up to the total.
8. The short run-out period for encounter submissions may not allow sufficient time for the MCOs to resolve encounter submission issues noted in previous reconciliation reports. This may result in lower completion percentages when reconciling the encounters to CDJ totals.
9. Opportunities for improving the encounter reconciliation process have been identified during analysis of the encounter data and cash disbursement journals, as well as frequent interactions with the MCOs, their delegated vendors, LDH, and the FAC. While we have attempted to account for these situations, other potential issues within the data may exist that have not yet been identified which may require us to restate a report or modify reconciliation processes in the future.